NovoCure (NVCR) to Announce Earnings on Thursday

NovoCure (NASDAQ:NVCR) will likely be announcing its Q2 2026 results before the market opens on Thursday, July 23rd. Analysts expect NovoCure to announce earnings of ($0.30) per share and revenue of $172.7180 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:00 AM ET.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). NovoCure had a negative return on equity of 50.82% and a negative net margin of 25.66%.The business had revenue of $174.06 million during the quarter, compared to analysts’ expectations of $167.77 million. During the same quarter in the previous year, the company posted ($0.31) EPS. The company’s revenue was up 12.3% compared to the same quarter last year. On average, analysts expect NovoCure to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NovoCure Price Performance

NovoCure stock opened at $15.94 on Tuesday. The company has a market cap of $1.85 billion, a P/E ratio of -10.42 and a beta of 0.94. NovoCure has a one year low of $9.82 and a one year high of $18.92. The business has a fifty day moving average of $16.69 and a two-hundred day moving average of $14.03. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.70 and a current ratio of 2.90.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Evercore reiterated an “outperform” rating on shares of NovoCure in a report on Friday, May 1st. Wells Fargo & Company boosted their price objective on shares of NovoCure from $13.50 to $17.00 and gave the stock an “equal weight” rating in a report on Monday, May 4th. Weiss Ratings upgraded shares of NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. JPMorgan Chase & Co. started coverage on shares of NovoCure in a report on Monday, July 13th. They issued a “neutral” rating and a $17.00 target price for the company. Finally, Wedbush reiterated a “neutral” rating and set a $18.00 price target on shares of NovoCure in a research report on Thursday, April 16th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, NovoCure has an average rating of “Hold” and a consensus target price of $23.60.

Insider Buying and Selling at NovoCure

In other NovoCure news, Director W Anthony Vernon sold 2,945 shares of NovoCure stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total transaction of $46,442.65. Following the completion of the transaction, the director owned 197,657 shares in the company, valued at approximately $3,117,050.89. The trade was a 1.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Allyson J. Ocean sold 2,945 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total transaction of $46,442.65. Following the completion of the sale, the director directly owned 11,324 shares in the company, valued at $178,579.48. This trade represents a 20.64% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 51,943 shares of company stock worth $893,171. Insiders own 5.52% of the company’s stock.

Institutional Investors Weigh In On NovoCure

Institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LLC grew its holdings in NovoCure by 178.0% during the 4th quarter. Corient Private Wealth LLC now owns 97,368 shares of the medical equipment provider’s stock valued at $1,259,000 after buying an additional 62,341 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in shares of NovoCure by 14.5% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider’s stock worth $422,000 after acquiring an additional 4,124 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of NovoCure in the fourth quarter valued at $33,000. XTX Topco Ltd lifted its position in shares of NovoCure by 159.2% in the fourth quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider’s stock valued at $760,000 after acquiring an additional 36,111 shares in the last quarter. Finally, Vestal Point Capital LP boosted its stake in shares of NovoCure by 31.2% during the fourth quarter. Vestal Point Capital LP now owns 525,000 shares of the medical equipment provider’s stock valued at $6,788,000 after acquiring an additional 125,000 shares during the last quarter. Hedge funds and other institutional investors own 84.61% of the company’s stock.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.